Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ALSEN.PA
- Price
- 0.35
- Stock movement down
- -0.02 (-5.14%)
- Company name
- Sensorion SA
- Exchange
- (PA ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Markedsværdi
- 105.34M
- Ent værdi
- 36.07M
- Pris/omsætning
- 12.11
- Pris/bog
- 1.26
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- -
- Efterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- -31.32%
- 1 års afkast
- -51.25%
- 3 års afkast
- -3.53%
- 5 års afkast
- -18.89%
- 10 års afkast
- -31.86%
Senest opdateret: 2025-06-22
UDBYTTE
ALSEN.PA betaler ikke udbytte
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | 12.11 |
| Pris til egenkapital | 1.26 |
| EV i forhold til salg | 4.15 |
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 300.12M |
| EPS (TTM) | -0.14 |
| FCF pr. aktie (TTM) | -0.15 |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | 8.70M |
| Bruttofortjeneste (TTM) | 7.18M |
| Driftsindkomst (TTM) | -24.83M |
| Nettoindkomst (TTM) | -35.96M |
| EPS (TTM) | -0.14 |
| EPS (1 år frem) | -0.13 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | 82.48% |
| Driftsmargin (TTM) | -285.35% |
| Fortjenstmargin (TTM) | -413.31% |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 87.34M |
| Nettotilgodehavender | 8.59M |
| Omsætningsaktiver i alt | 97.96M |
| Goodwill | 0.00 |
| Immaterielle aktiver | 621.00K |
| Ejendomme, anlæg og udstyr | 0.00 |
| Sum aktiver | 101.53M |
| Kreditor | 7.69M |
| Kortfristet/nuværende langsigtet gæld | 2.35M |
| Summen af kortfristede forpligtelser | 14.17M |
| Sum gæld | 18.07M |
| Aktionærernes egenkapital | 83.46M |
| Materielle nettoaktiver | 0.00 |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | -38.29M |
| Investeringsudgifter (TTM) | 1.27M |
| Fri pengestrøm (TTM) | -39.81M |
| Udbetalt udbytte (TTM) | 0.00 |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | -43.08% |
| Afkast af aktiver | -35.42% |
| Afkast af investeret kapital | -42.57% |
| Kontant afkast af investeret kapital | -47.13% |
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 0.36 |
| Daglig høj | 0.38 |
| Daglig lav | 0.35 |
| Daglig volumen | 248K |
| Højeste gennem alle tider | 18.50 |
| 1 års analytiker estimat | 2.38 |
| Beta | 1.34 |
| EPS (TTM) | -0.14 |
| Udbytte pr. aktie | - |
| Ex-div dato | - |
| Næste dato for resultatpræsentation | - |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| ALSEN.PA | S&P500 | |
| Nuværende prisfald fra top notering | -98.10% | -3.04% |
| Højeste prisfald | -99.16% | -56.47% |
| Højeste efterår dato | 24 Apr 2025 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -84.65% | -11.04% |
| Gennemsnitlig tid til nyt højdepunkt | 163 days | 12 days |
| Maks. tid til nyt højdepunkt | 2546 days | 1805 days |
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
105.34M
Markedsværdi kategori
Small-cap
Beskrivelse
Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. Its pipeline includes various products in the development stage for restoring, treating, and preventing inner ear related disorders. The company's product portfolio includes SENS-401 SSNHL, which has completed Phase 2 clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2 clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, which is in Phase 2 clinical trial for the treatment of hearing preservation after cochlear implantation. It is also developing OTOF-GT (SENS-501), a gene therapy development program that has completed Phase 1 clinical trial to restore hearing in people living with Otoferlin deficiency; and GJB2-GT, a gene therapy development program, which is in pre-clinical trial to restore hearing in people living with hearing loss due to mutations in the GJB2 gene. The company was incorporated in 2009 and is headquartered in Montpellier, France.
Personale
61
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
France
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
MONTPELLIER, France, July 01, 2025--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, t...
1. juli 2025
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small becau...
16. juni 2025
Investing.com -- Citi analysts have placed Qorvo (NASDAQ:QRVO) and Skyworks Solutions (NASDAQ:SWKS), Inc. on an "upside 90-day catalyst watch," anticipating better-than-expected June and September qua...
10. juni 2025
Skyworks (SWKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
6. juni 2025
Fabless chip and software maker Broadcom (NASDAQ:AVGO) will be announcing earnings results tomorrow after the bell. Here’s what to look for.
4. juni 2025
SWKS and QRVO ride tailwinds from WiFi 7, IoT, and 5G growth, even as macro pressures weigh on radio frequency chipmakers.
2. juni 2025
The rapid proliferation of the edge IoT, AI data centers and automotive electrification, as well as the adoption of WiFi 6E and WiFi 7, is enhancing the prospects of SWKS and QRVO despite challenging ...
30. maj 2025
QRVO expands DOCSIS 4.0 lineup with high-efficiency amplifiers aimed at reducing broadband infrastructure costs.
30. maj 2025
Qorvo (QRVO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
29. maj 2025
Stiff competition and a shift in demand towards entry-tier smartphones pushed Qorvo shares down about 38% last year. In April, Starboard said it delivered a letter to Qorvo, nominating Feld for elect...
19. maj 2025
Næste side